Results 11 to 20 of about 5,008,934 (241)

Pharmacokinetics ofp-Aminohippuric Acid and Inulin in Rabbits with Aristolochic Acid Nephropathy [PDF]

Advances in Pharmacological Sciences, 2011
The characteristics of aristolochic acid nephropathy (AAN) are interstitial fibrosis and atrophy of the proximal tubules, but with no change in glomeruli.
Chiao-Shih Tseng, Shih‐Ming Chen, Shu‐Chen Chien, Kuang‐Yang Hsu   +3 more
core   +8 more sources

Measurement of urinary para-aminohippuric acid in glycosurie diabetics

Kidney International, 1988
R. Neil Dalton, Martin Wiseman, Charles Turner, Giancarlo Viberti   +3 more
openalex   +4 more sources

Active Mammary Excretion of N4-Acetylated p-Aminohippuric Acid*) [PDF]

Acta Veterinaria Scandinavica, 1969
Different excretion patterns were observed for p-amino- hippuric acid and its acetylated metabolite in mammary excretion experiments in goats and cows. The excretion of p-aminohippuric acid conformed to passive diffusion of the non-protein bound and un-ionized fraction (Rasmussen 1958, 1966) as described by Miller et al. (1967).
Folke Rasmussen
openalex   +4 more sources

SYNTHESIS OF p-AMINOHIPPURIC ACID BY MITOCHONDRIA OF MOUSE LIVER HOMOGENATES

Journal of Biological Chemistry, 1950
Ruth K. Kielley, Walter Schneider
openalex   +4 more sources

Novel odd-chain cyclopropane fatty acids: detection in a mammalian lipidome and uptake by hepatosplanchnic tissues. [PDF]

J Lipid Res
Microbe-produced molecules (xenometabolites) found in foods or produced by gut microbiota are increasingly implicated in microbe-microbe and microbe-host communication.
Sobhi HF, Mercer KE, Lan RS, Yeruva L, Ten Have GAM, Deutz NEP, Piccolo BD, Debédat J, Pack LM, Adams SH.   +9 more
europepmc   +3 more sources

System Identification of the Low-Dose Kinetics of p-Aminohippuric Acid [PDF]

cclm, 1995
The renal clearance of p-aminohippuric acid, due to tubular secretion in addition to glomerular filtration, can only be determined by kinetic experiments. Maximal information can be gained from observed temporal marker concentration profiles by fitting dynamic mathematical models of the processes involved, such as absorption, distribution, and ...
Willibald Estelberger, Sabine Zitta, Thomas Lang�, Frank Mayer, Astrid Mauric, Sabine Horn, Herwig Holzer, W. Petek, Gilbert Reibnegger   +8 more
openalex   +5 more sources

Maternal dexamethasone exposure does not affect glucose tolerance but alters renal haemodynamics in F1 rats in a sex‐dependent manner

Endocrinology, Diabetes &Metabolism, Volume 6, Issue 6, November 2023., 2023
Maternal dexamethasone treatment caused glomerular hypertrophy and a decline in renal function and effective renal plasma flow in 4‐month‐old male offspring with no changes detected in females of the same age. The expression of sodium‐glucose transporter‐2 in renal membrane fractions was not affected by dexamethasone treatment suggesting that it does ...
Slava A. Malatiali, Narayana Kilarkaje, Maie Al‐Bader   +2 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2023/24: Transporters

British Journal of Pharmacology, Volume 180, Issue S2, Page S374-S469, October 2023., 2023
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and over 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links
Stephen P. H. Alexander, Doriano Fabbro, Eamonn Kelly, Alistair A. Mathie, John A. Peters, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Jamie A. Davies, Laura Amarosi, Catriona M. H. Anderson, Philip M. Beart, Stefan Broer, Paul A. Dawson, Gergely Gyimesi, Bruno Hagenbuch, James R. Hammond, Jules C. Hancox, Michal Hershfinkel, Ken‐ichi Inui, Yoshikatsu Kanai, Stephan Kemp, Edmund R. S. Kunji, Gavin Stewart, Sotiria Tavoulari, David T. Thwaites, Tiziano Verri   +27 more
wiley   +1 more source

Evaluation of Drug‐Drug Interactions of Ensitrelvir, a SARS‐CoV‐2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies

The Journal of Clinical Pharmacology, Volume 63, Issue 8, Page 918-927, August 2023., 2023
Abstract Drug‐drug interaction potentials of ensitrelvir, a novel oral inhibitor of 3C‐like protease of severe acute respiratory syndrome coronavirus 2, for drug transporters were evaluated by in vitro and clinical studies. The target drug transporters assessed were P‐glycoprotein (P‐gp), breast cancer resistance protein (BCRP), organic anion ...
Ryosuke Shimizu, Takanobu Matsuzaki, Ryoko Oka, Takuhiro Sonoyama, Takahiro Fukuhara, Aya Kuwata, Yumiko Matsuo, Ryuji Kubota   +7 more
wiley   +1 more source

Identification of fecal microbiome signatures associated with familial longevity and candidate metabolites for healthy aging

Aging Cell, Volume 22, Issue 6, June 2023., 2023
This study depicted the metabolite and microbiota trajectories across aging. Long‐lived subjects from the familial longevity cohort harbored a distinguished microbiome signature. A candidate metabolite, pinane thromboxane A2 (PTA2), was consistently higher in the individuals of familial longevity and their descendants.
Junli Gong, Sanxin Liu, Shisi Wang, Hengfang Ruan, Qianqian Mou, Ping Fan, Tao Chen, Wei Cai, Yongjun Lu, Zhengqi Lu   +9 more
wiley   +1 more source